773 related articles for article (PubMed ID: 19186105)
21. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.
Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stüve O; Arnold DL; Spychala ME; McConville KC; Harris KM; Phippard D; Georges GE; Wundes A; Kraft GH; Bowen JD
JAMA Neurol; 2015 Feb; 72(2):159-69. PubMed ID: 25546364
[TBL] [Abstract][Full Text] [Related]
22. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
[TBL] [Abstract][Full Text] [Related]
24. Autologous stem cell transplant in adult multiple sclerosis patients: A study from North India.
Dayama A; Bhargava R; Kurmi SR; Jain S; Dua V
Neurol India; 2020; 68(2):454-457. PubMed ID: 32415023
[TBL] [Abstract][Full Text] [Related]
25. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
26. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
27. Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center.
Ruiz-Argüelles GJ; Olivares-Gazca JC; Olivares-Gazca M; Leon-Peña AA; Murrieta-Alvarez I; Cantero-Fortiz Y; Gomez-Cruz GB; Ruiz-Argüelles A; Priesca-Marin M; Ruiz-Delgado GJ
Clin Exp Immunol; 2019 Dec; 198(3):351-358. PubMed ID: 31394007
[TBL] [Abstract][Full Text] [Related]
28. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
[TBL] [Abstract][Full Text] [Related]
29. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
30. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Steinmiller KC; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stuve O; Arnold DL; Wener MH; Georges GE; Wundes A; Kraft GH; Bowen JD
Neurology; 2017 Feb; 88(9):842-852. PubMed ID: 28148635
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
32. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Goodin D; Hartung HP; Jeffery D; Kappos L; Boateng F; Filippov V; Groth M; Knappertz V; Kraus C; Sandbrink R; Pohl C; Bogumil T; ; O'Connor P; Filippi M; Arnason B; Cook S; Goodin D; Hartung HP; Kappos L; Jeffery D; Comi G
Lancet Neurol; 2009 Oct; 8(10):889-97. PubMed ID: 19729344
[TBL] [Abstract][Full Text] [Related]
33. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients.
Burt RK; Traynor AE; Cohen B; Karlin KH; Davis FA; Stefoski D; Terry C; Lobeck L; Russell EJ; Goolsby C; Rosen S; Gordon LI; Keever-Taylor C; Brush M; Fishman M; Burns WH
Bone Marrow Transplant; 1998 Mar; 21(6):537-41. PubMed ID: 9543056
[TBL] [Abstract][Full Text] [Related]
34. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
[TBL] [Abstract][Full Text] [Related]
35. Intense immunosuppressive therapy followed by autologous peripheral blood selected progenitor cell reinfusion for severe autoimmune disease.
Musso M; Porretto F; Crescimanno A; Bondi F; Polizzi V; Scalone R
Am J Hematol; 2001 Feb; 66(2):75-9. PubMed ID: 11421302
[TBL] [Abstract][Full Text] [Related]
36. Autologous non-myeloablative haematopoietic stem cell transplantation for refractory systemic vasculitis.
Statkute L; Oyama Y; Barr WG; Sufit R; Ho S; Verda L; Loh Y; Yaung K; Quigley K; Burt RK
Ann Rheum Dis; 2008 Jul; 67(7):991-7. PubMed ID: 17947303
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population.
Xu J; Ji BX; Su L; Dong HQ; Sun WL; Wan SG; Liu YO; Zhang P; Liu CY
Ann Hematol; 2011 Mar; 90(3):343-8. PubMed ID: 20872003
[TBL] [Abstract][Full Text] [Related]
38. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study.
Traynor AE; Schroeder J; Rosa RM; Cheng D; Stefka J; Mujais S; Baker S; Burt RK
Lancet; 2000 Aug; 356(9231):701-7. PubMed ID: 11085688
[TBL] [Abstract][Full Text] [Related]
39. Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis.
Samijn JP; te Boekhorst PA; Mondria T; van Doorn PA; Flach HZ; van der Meché FG; Cornelissen J; Hop WC; Löwenberg B; Hintzen RQ
J Neurol Neurosurg Psychiatry; 2006 Jan; 77(1):46-50. PubMed ID: 16361591
[TBL] [Abstract][Full Text] [Related]
40. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
